IVE:LIFE - OLder heart failure patients Initiated on iVabradinE in UK quaLIty of liFE

Servier Laboratories Ltd (UK)0 个研究点目标入组 220 人开始时间: 2013年11月18日最近更新: 2018年9月24日

适应症

试验速览

•Heart failure patients:
•1. Aged 70 years or older
•2. Where a decision has already been made to initiate ivabradine for treatment of HF as per licensed indication for heart failure,
•2.1. Chronic heart failure New York Heart Association (NYHA) Class II to IV with systolic dysfunction
•2.1. In sinus rhythm with resting HR =75 beats per min
•2.3. In combination with standard therapy including beta blockers or when beta blockers are contraindicated or not tolerated
•3. Who have given their informed consent

•1. Patients not receiving ivabradine as planned within 2 weeks from inclusion in the study
•2. Patients no longer under the care of a study physician (named in the delegation log)
•3. Patients enrolled or planning to be enrolled into an interventional clinical trial
•4. Patients prescribed ivabradine in a manner not consistent with the Summary of Product Characteristics (SmPC) for congestive heart failure (CHF) with left ventricular systolic dysfunction (LVSD)
•5. Patients with cognitive impairment to such a degree that the investigator feels they would be unable to complete the study

发起方

Servier Laboratories Ltd (UK)